Muramyl Dipeptides

  • M. Parant
  • L. Chedid
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 85)

Abstract

Synthetic muramyl dipeptide or MDP (AcMur-l-Ala-d-iGln) is able to replace killed mycobacteria in complete Freund’s adjuvant (CFA) for the induction of both humoral and cellular immunity (Ellouz et al. 1974). The structural requirements for the adjuvant activity were investigated by comparing a large series of analogs, and found to be rather narrow. Initially, the adjuvant effect of MDP was demonstrated in a water-in-oil emulsion. However, its clinical use became a reasonable goal when it was shown to possess immunoadjuvant properties, even when administered in saline (Chedid et al. 1976; Audibert et al. 1976), and when synthetic analogs lacking untoward effects were prepared (Chedid et al. 1982; Allison et al. 1986). Some of the steps in the research into the biologic adjuvant effects of MDPs have been reported in reviews articles (Adam 1985; Audibert et al. 1985; Takada and Kotani 1985).

Keywords

Thymidine Pertussis Beryllium Dipeptide Mycobacterium 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abehsira-Amar O, Damais C, Parant M, Chedid L (1985) Strain dependence of muramyl dipeptide-induced LAF (IL-1) release by murine-adherent peritoneal cells. J Immunol 134: 365–368PubMedGoogle Scholar
  2. Adam A (1985) Synthetic adjuvants. Wiley, New YorkGoogle Scholar
  3. Allison AC (1984) Immunological adjuvants and their mode of action. In: Bell R, Torrigiani G (eds) New approaches to vaccine development. Schwabe, Basel, p 133Google Scholar
  4. Allison AC (1985) The interleukin-1 family of molecules. Bioessays 3: 260–263PubMedCrossRefGoogle Scholar
  5. Allison AC, Byars NE, Waters RV (1986) Immunologic adjuvants: efficacy and safety considerations. In: Nerbig RM, Gough PM, Kaeberle ML, Whetstone CA (eds) Advances in carriers and adjuvants for veterinary biologics. The Iowa State University Press, Ames, p 91Google Scholar
  6. Anderson AO (1985) Multiple effects of immunological adjuvants on lymphatic microenvironments. I. Role of immunologically-relevant angiogenesis in the mechanisms of action of CFA, MDP and avridine. Int J Immunother 1: 185–195Google Scholar
  7. Audibert F, Chedid L, Lefrancier P, Choay J (1976) Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components. Cell Immunol 21: 243–249PubMedCrossRefGoogle Scholar
  8. Audibert F, Leclerc C, Chedid L (1985) Muramyl peptides as immunopharmacological responses modifiers. In: Torrence PF (ed) Biological response modifiers. Academic, New York, p 307Google Scholar
  9. Azuma I, Sugimura K, Taniyama T, Yamawaki M, Yamamura Y, Kusumoto S, Okada S, Shiba T (1976) Adjuvant activity of mycobacterial fractions: immunological properties of synthetic N-acetylmuramyl dipeptide and related compounds. Infect Immun 14: 18–27PubMedGoogle Scholar
  10. Azuma I, Sugimura K, Yamawaki M, Uemiya M, Kusumoto S, Okada S, Shiba T, Yamamura Y (1978) Adjuvant activity of synthetic 6–0-“mycoloyl”-N-acetylmuramyl-L-alanyl-D-isoglutamine and related compounds. Infect Immun 20: 600–607PubMedGoogle Scholar
  11. Bahr GM, Eshhar Z, Ben-Yitzhak R, Modabber FZ, Arnon R, Sela M, Chedid L (1983) Monoclonal antibodies to the synthetic adjuvant muramyl dipeptide: characterization of the specificity. Molec Immunol 20: 745–752CrossRefGoogle Scholar
  12. Bahr GM, Modabber FZ, Morin A, Terrier M, Eyquem A, Chedid L (1984) Regulation by muramyl dipeptide ( MDP) of the lymphoproliferative responses and polyclonal activation of human peripheral blood mononuclear cells. Clin Exp Immunol 57: 178–186Google Scholar
  13. Behbehani K, Beller DI, Unanue ER (1985) The effects of beryllium and other adjuvants on la expression by macrophages. J Immunol 134: 2047–2049PubMedGoogle Scholar
  14. Brumer E, Stevens DA (1981) Opposite modulation of lymph node cell and spleen cell responses to mitogens by muramyl dipeptide and its desmethyl analog. Cell Immunol 59: 195–204CrossRefGoogle Scholar
  15. Brumer E, Stevens DA (1985) Mechanisms in opposite modulation of spleen cell and lymph node cells responses to mitogens following muramyl dipeptide treatment in vivo. Cell Immunol 91: 505–514CrossRefGoogle Scholar
  16. Chedid L, Audibert F, Lefrancier P, Choay J, Lederer E (1976) Modulation of the immune response by a synthetic adjuvant and analogs. Proc Natl Acad Sci USA 73: 2472–2475PubMedCrossRefGoogle Scholar
  17. Chedid LA, Parant MA, Audibert FM, Riveau GJ, Parant FJ, Lederer E, Choay JP, Lefrancier PL (1982) Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity. Infect Immun 35: 417–424PubMedGoogle Scholar
  18. Damais C, Parant M, Chedid L (1977) Nonspecific activation of murine spleen cells in vitro by a synthetic immunoadjuvant ( N-acetylmuramyl-L-analyl-D-isoglutamine ). Cell Immunol 34: 49–56Google Scholar
  19. Damais C, Parant M, Chedid L, Lefrancier P, Choay J (1978) In vitro spleen cell responsiveness to various analogs of MDP ( N-acetylmuramyl-L-alanyl-D-isoglutamine), a synthetic immunoadjuvant, in MDP high-responder mice. Cell Immunol 35: 173–179Google Scholar
  20. Damais C, Riveau G, Parant M, Gerota J, Chedid L (1982) Production of lymphocyte activating factor in the absence of endogenous pyrogen by rabbit or human leukocytes stimulated by a muramyl dipeptide derivative. Int J Immunopharmacol 4: 451–462PubMedCrossRefGoogle Scholar
  21. Eggers AE, Tannin L (1984) T-cell nature of adjuvant peptide-induced antitumor cell-mediated cytotoxicity. J Biol Response Mod 3: 387–390PubMedGoogle Scholar
  22. Ellouz F, Adam A, Ciorbaru R, Lederer E (1974) Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun 59: 1317–1325PubMedCrossRefGoogle Scholar
  23. Ferguson TA, Fish LA, Baxter CS, Michael JG (1982) Concomitant enhancement of B-cell mitogenesis and inhibition of antibody synthesis by a phorbol ester (41481). Proc Soc Exp Biol Med 171: 83–87PubMedGoogle Scholar
  24. Ferguson TA, Krieger NJ, Pesce A, Michael JG (1983) Enhancement of antigen-specific suppression by muramyl dipeptide. Infect Immun 39: 800–806PubMedGoogle Scholar
  25. Février M, Duquenne C, Birrien JL, Liacooulos P (1979) Maturation of nu/nu mouse spleen pre-T cells induced in vitro by muramyl dipeptide. In: Kaplan JG (ed) Molecular basis of immune cell function. Elsevier, Amsterdam, p 499Google Scholar
  26. Gisler RH, Dietrich FM, Baschang C, Brownbill A, Schumann G, Staber FG, Tarcsay L, Wachsmuth ED, Dukor P (1979) New developments in drugs enhancing the immune response: activation of lymphocytes and accessory cells by muramyl dipeptides. In: Turk JL, Parker D (eds) Drugs and immune responsiveness. McMillan, London, p 133Google Scholar
  27. Hadden J, Englard A, Sadlik JR, Hadden EM (1979) The comparative effects of isoprinosine, levamisole, muramyl dipeptide and SM 1213 on lymphocyte and macrophage proliferation and activation in vitro. Int J Immunopharmacol 1: 17–27PubMedCrossRefGoogle Scholar
  28. Hamaoka T, Takai Y, Kosugi A, Mizushima Y, Shima J, Kusama T, Fujiwara H (1985) The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptenic MDP derivative cross-reactive with Bacillus Calmette-Guérin and its application to enhanced induction of tumor immunity. Cancer Immunol Immunother 20: 183–188Google Scholar
  29. Heymer B, Finger H, Wirsing CH (1978) Immunoadjuvant effects of the synthetic muramyl dipeptide ( MDP) N-acetylmuramyl-Lalanyl-D-isoglutamine. Z Immunitätsforsch 155: 87–92Google Scholar
  30. Igarashi T, Okada M, Azuma I, Yamamura Y (1977) Adjuvant activity of synthetic N-acetylmuramyl-L-alanyl-D-isoglutamine and related compounds on cell-mediated cytotoxicity in syngeneic mice. Cell Immunol 34: 270–278PubMedCrossRefGoogle Scholar
  31. Iribe H, Koga T, Onoue K, Kotani S, Kusumoto S, Shiba T (1982) Enhanced production of T-cell activating factors by macrophages exposed in vitro to MDP and its adjuvant-active analogs. In: Yamamura Y, Kotani S, Azuma I, Koda A, Shiba T (eds) Immunomodulation by microbial products and related synthetic compounds. Excerpta Medica, Amsterdam, p 213 (International congress series, vol 563 )Google Scholar
  32. Kato K, Yamamoto KI, Kimura T, Azuma I, Askenase PW (1984) Suppression of BCG cell wall induced delayed type hypersensitivity by pretreatment with killed BCG: induction of nonspecific suppressor T-cells by the adjuvant portion (MDP) and of specific suppressor T-cells by the antigen portion ( TAP ). J Immunol 132: 2790–2795Google Scholar
  33. Kishimoto T, Hirai Y, Nakanishi K, Azuma I, Nagamatsu A, Yamamura Y (1979) Regulation of antibody response in different immunoglobulin classes. VI. Selective suppression of IgE response by administration of antigen-conjugated muramyl peptides. J Immunol 123: 2709–2715Google Scholar
  34. Kiyono H, McGhee JR, Kearney JF, Michalek SM (1982) Enhancement of in vitro immune responses of murine Peyer’s patch cultures by concanavalin A, muramyl dipeptide and lipopolysaccharide. Scand J Immunol 15: 329–339PubMedCrossRefGoogle Scholar
  35. Kotani S, Watanabe Y, Kinoshita F, Shimono T, Morisaki I, Shiba T, Kusumoto S, Tarumi Y, Ikenaka K (1975) Immunoadjuvant activities of synthetic N-acetylmuramyl peptides or -amino acids. Biken J 18: 105–111PubMedGoogle Scholar
  36. Kurt-Jones EA, Virgin HW, Unanue ER (1985) Relationship of macrophage Ia and mem-brane IL-1 expression to antigen presentation. J Immunol 135: 3652–3654PubMedGoogle Scholar
  37. Leclerc C, Chedid L (1982) Macrophage activation by synthetic muramyl peptides. In: Pick E (ed) Lymphokines, vol 7. Academic, New York, pp 1–21Google Scholar
  38. Leclerc C, Chedid L (1983) Suppression of IL-2 production by muramyl dipeptide and derivatives. In: Oppenheim JJ, Cohen S (eds) Interleukins, lymphokines and cytokines. Academic, New York, p 699Google Scholar
  39. Leclerc C, Audibert F, Chedid L (1978) Influence of a synthetic adjuvant ( MDP) on qualitative and quantitative changes of serum globulins. Immunology 35: 963–970Google Scholar
  40. Leclerc C, Juy D, Bourgeois E, Chedid L (1979a) In vivo regulation of humoral and cellular immune responses of mice by a synthetic adjuvant, N-acetylmuramyl-L-alanyl-D-isoglutamine, muramyl dipeptide or MDP. Cell Immunol 45: 199–206Google Scholar
  41. Leclerc C, Bourgeois E, Chedid L (1979b) Enhancement by MDP of in vitro nude mice responses to a T-dependent antigen. Immunol Commun 8: 55–64PubMedGoogle Scholar
  42. Löwy I, Bona C, Chedid L (1977) Target cells for the activity of a synthetic adjuvant: muramyl dipeptide. Cell Immunol 29: 195–199PubMedCrossRefGoogle Scholar
  43. Löwy I, Leclerc C, Bourgeois E, Chedid L (1980) Inhibition of mitogen induced polyclonal activation by a synthetic adjuvant, muramyl dipeptide ( MDP ). J Immunol 124: 320325Google Scholar
  44. Matter A (1979) The effects of muramyl dipeptide (MDP) in cell-mediated immunity. A comparison between in vitro and in vivo systems. Cancer Immunol Immunother 6: 201–210CrossRefGoogle Scholar
  45. Morisaki I, Michalek SM, Harmon CC, Torii M, Hamada S, McGhee JR (1983) Effective immunity to dental caries-enhancement of salivary anti-Streptococcus mutans antibody responses with oral adjuvants. Infect Immun 40: 577–591PubMedGoogle Scholar
  46. Nagao S, Miki T, Tanaka A (1981) Macrophage activation by muramyl dipeptide ( MDP) without lymphocyte participation. Microbiol Immunol 25: 41–50Google Scholar
  47. Ohkuni H, Norose Y, Ohta M, Hayama M, Kimura Y, Tsujimoto M, Kotani S, Shiba T, Kusumoto S, Yokogawa K, Kawata S (1979) Adjuvant activities in production of reaginic antibody by bacterial cell wall peptidoglycan or synthetic N-acetylmuramyl di-peptides in mice. Infect Immun 24: 313–318PubMedGoogle Scholar
  48. Oppenheim JJ, Togawa A, Chedid L, Mizel S (1980) Components of mycobacteria and muramyl dipeptide with adjuvant activity induce lymphocyte activating factor. Cell Immunol 50: 71–81PubMedCrossRefGoogle Scholar
  49. Oppenheim JJ, Kovacs EJ, Matsushima K, Durum SK (1986) There is more than one interleukin-1. Immunol Today 7: 45–56CrossRefGoogle Scholar
  50. Pabst MJ, Johnston RB (1980) Increased production of superoxide anion by macrophages exposed in vitro to muramyl dipeptide or lipopolysaccharide. J Exp Med 151: 101–114PubMedCrossRefGoogle Scholar
  51. Parant M (1979) Biologic properties of a new synthetic adjuvant muramyl dipeptide (MDP). Springer Semin Immunopathol 2: 101–118CrossRefGoogle Scholar
  52. Parant MA, Audibert FM, Chedid LA, Level MR, Lefrancier PL, Choay JP, Lederer E (1980) Immunostimulant activities of a lipophilic muramyl dipeptide derivative and of desmuramyl peptidolipid analogs. Infect Immun 27: 825–831Google Scholar
  53. Phillips NC, Bahr GM, Modabber RZ, Chedid L (1984) Modulation of the growth of murine thymoma cell lines having different Lyt-phenotypes by MDP and MDP(D-D): macrophage-mediated inhibition of in vitro cell growth. Int J Immunopharmacol 6: 577–585PubMedCrossRefGoogle Scholar
  54. Prunet J, Birnen JL, Panijel J, Liacopoulos P (1978) On the mechanisms of early recovery of specifically depleted lymphoid cell populations by nonspecific activation of T-cells. Cell Immunol 37: 151–161PubMedCrossRefGoogle Scholar
  55. Reichert C, Carelli C, Jolivet M, Audibert F, Lefrancier P, Chedid L (1980) Synthesis of conjugate containing N-acetylmuramyl-L-analyl-D-isoglutamine (MDP). Their use as hapten-carrier systems. Mol Immunol 17: 357–363Google Scholar
  56. Saito-Taki T, Tanabe MJ, Mochizuki H, Matsumoto T, Nakano M, Takada H, Tsujimoto M, Kotani S, Kusumoto S, Shiba T, Yokogawa K, Kawata S (1980) Polyclonal B-cell activation by cell wall preparations of gram-positive bacteria. Microbiol Immunol 24: 209–218PubMedGoogle Scholar
  57. Saito-Taki T, Nakano M, Kiso M, Hasegawa A (1985) Comparison of murine B-cell clonal expansions by synthetic lipid A and muramyl dipeptide analogs. Microbiol Immunol 29: 1111–1120PubMedGoogle Scholar
  58. Sharma SD, Tsai V, Krahenbuhl JL, Remington JS (1981) Augmentation of mouse natural killer cell activity by muramyl dipeptide and its analogs. Cell Immunol 62: 101–109PubMedCrossRefGoogle Scholar
  59. Souvannavong V, Adam A (1980) Opposite effects of the synthetic adjuvant N-acetylmuramyl-L-alanyl-D-isoglutamine on the immune response in mice depending on experimental conditions. Eur J Immunol 10: 654–656PubMedCrossRefGoogle Scholar
  60. Souvannavong V, Adam A (1984) Restoration and stimulation of the in vitro immune response of B-cells to sheep erythrocytes by interleukines and muramyl dipeptide ( MDP ). Biochem Biophys Res Commun 125: 431–439Google Scholar
  61. Specter S, Friedman H, Chedid L (1977) Dissociation between the adjuvant vs mitogenic activity of a synthetic muramyl dipeptide for murine splenocytes. Proc Soc Exp Biol Med 155: 349–352PubMedGoogle Scholar
  62. Specter S, Cimprich R, Friedman H, Chedid L (1978) Stimulation of enhanced in vitro immune response by the synthetic adjuvant, muramyl dipeptide. J Immunol 120: 487–491PubMedGoogle Scholar
  63. Staruch MJ, Wood DD (1982) Genetic influence on the adjuvanticity of muramyl dipeptide in vivo. J Immunol 128: 155–181PubMedGoogle Scholar
  64. Staruch MJ, Wood DD (1983) The adjuvanticity of interleukin-1 in vivo. J Immunol 130: 2191–2194PubMedGoogle Scholar
  65. Sugimoto M, Germain RN, Chedid L, Benacerraf B (1978) Enhancement of carrier-specific helper T-cell function by the synthetic adjuvant. N-acetylmuramyl-L-alanyl-D-isoglutamine ( MDP ). J Immunol 120: 980–981Google Scholar
  66. Sugimura K, Uemiya M, Saiki I, Azuma I, Yamamura Y (1979) The adjuvant activity of synthetic N-acetyl muramyl dipeptide: evidence of initial target cells for the adjuvant activity. Cell Immunol 43: 137–149PubMedCrossRefGoogle Scholar
  67. Takada H, Kotani S (1985) Immunopharmacological activities of synthetic muramyl peptides. In: Stewart-Tull DES, Davies M (eds) Immunology of the bacterial cell envelope. Wiley, Chichester, p 119Google Scholar
  68. Talmadge JE, Schneider M, Collins M, Phillips H, Herberman RB, Wiltrout RH (1985) Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE. J Immunol 135: 1477–1483PubMedGoogle Scholar
  69. Tanaka A, Nagao S, Saito R, Kotani S, Kusumoto S, Shiba T (1977) Correlation of stereo-chemically specific structure in muramyl dipeptide between macrophage activation and adjuvant activity. Biochem Biophys Res Commun 77: 621–627PubMedCrossRefGoogle Scholar
  70. Taubman MA, Ebersole JL, Smith DJ, Stack W (1983) Adjuvants for secretory immune responses. Ann NY Acad Sci 409: 637–649PubMedCrossRefGoogle Scholar
  71. Waters RV, Ferraresi RW (1980) Muramyl dipeptide stimulation of particle clearance in several animal species. J Reticuloendothel Soc 28: 457–471PubMedGoogle Scholar
  72. Watson J, Whitlock C (1978) Effect of a synthetic adjuvant on the induction of primary immune responses in T-cell-depleted spleen cultures. J Immunol 121: 383–389PubMedGoogle Scholar
  73. Wood DD, Staruch MJ (1981) Control of the mitogenicity of muramyl dipeptide. Int J Im-munopharmacol 3: 31–44Google Scholar
  74. Wuest B, Wachsmuth E (1982) Stimulatory effect of N-acetylmuramyl dipeptide in vivo: proliferation of bone marrow progenitor cells in mice. Infect Immun 37: 452–462PubMedGoogle Scholar
  75. Yamamura Y, Azuma I, Sugimura K, Yamawaki M, Kusumoto S, Okada S, Shiba T (1976) Adjuvant activity of 6-O-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine. Gann 67: 867–877PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • M. Parant
  • L. Chedid

There are no affiliations available

Personalised recommendations